NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
T. Eyre,R. Clifford,19 Authors,A. Schuh
2016 · DOI: 10.1111/bjh.14177
British Journal of Haematology · 65 Citations
TLDR
Standard immunochemotherapy for RS remains wholly inadequate for unselected RS, and CHOP‐O with ofatumumab maintenance provides minimal benefit beyond CHOP plus rutuximab.